Trials / Conditions / Stage III Renal Pelvis Cancer AJCC v8

Stage III Renal Pelvis Cancer AJCC v8

10 registered clinical trials studyying Stage III Renal Pelvis Cancer AJCC v8 — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remov NCT06661720	Alliance for Clinical Trials in Oncology	Phase 3
Active Not Recruiting	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in NCT05092958	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104	M.D. Anderson Cancer Center	Phase 2
Terminated	Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary NCT04398368	Mayo Clinic	Phase 2
Completed	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C NCT03513952	National Cancer Institute (NCI)	Phase 2
Completed	Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Partici NCT03617913	Mayo Clinic	Phase 2
Active Not Recruiting	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta NCT03237780	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer NCT00749892	M.D. Anderson Cancer Center	Phase 2